miR-153-3p suppresses the differentiation and proliferation of neural stem cells via targeting GPR55

Xiaolin Dong¹, Hui Wang², Liping Zhan¹, Qingyun Li¹, Yang Li¹, Gang Wu¹, Huan Wei¹, Yanping Li¹

¹Department of Neurology, The Affiliated Yan'an Hospital of Kunming Medical University, Kunming 650051, Yunnan, China ²Department of Gastroenterology, The Affiliated Yan'an Hospital of Kunming Medical University, Kunming 650051, Yunnan, China

Correspondence to: Yanping Li; email: liyanping@kmmu.edu.cnKeywords: miR-153-3p, Alzheimer's disease, GPR55, neurodegenerative diseasesReceived: October 14, 2020Accepted: April 29, 2021Published: August 27, 2023

Copyright: © 2022 Dong et al. This is an open access article distributed under the terms of the <u>Creative Commons Attribution</u> <u>License</u> (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Alzheimer's disease is the most frequent neurodegenerative disease and is characterized by progressive cognitive impairment and decline. NSCs (neural stem cells) serve as beneficial and promising adjuncts to treat Alzheimer's disease. This study aimed to determine the role of miR-153-3p expression in NSC differentiation and proliferation. We illustrated that miR-153-3p was decreased and GPR55 was upregulated during NSC differentiation. IL-1 β can induce miR-153-3p expression. Luciferase reporter analysis noted that elevated expression of miR-153-3p significantly inhibited the luciferase value of the WT reporter plasmid but did not change the luciferase value of the mut reporter plasmid. Ectopic miR-153-3p expression suppressed GPR55 expression in NSCs and identified GPR55 as a direct target gene of miR-153-3p. Ectopic expression of miR-153-3p inhibited NSC growth and differentiation into astrocytes and neurons. Elevated expression of miR-153-3p inhibited NSC differentiation and proliferation by targeting GPR55 expression. These data suggested that miR-153-3p may act as a clinical target for the therapeutics of neurodegenerative diseases.

INTRODUCTION

AD (Alzheimer's disease) is the most frequent neurodegenerative disease and is characterized by progressive cognitive impairment and decline [1–4]. However, available therapeutic methods for AD are still lacking because of the unclear pathogenesis and etiology of this disease [5–7]. NSCs (neural stem cells) are multipotent and self-renewing cells found in the central nervous system of adults and developing mammals [8–10]. These stem cells differentiate into oligodendrocytes, astrocytes and neurons and serve as beneficial and promising adjuncts to treat neurological diseases such as spinal cord injuries, Parkinson's disease, brain trauma and AD [11–14]. However, many challenges must be solved before the clinical use of NSCs. MiRNAs are a family of 19- to 24-nucleotide noncoding endogenous RNAs that modulate gene expression at the posttranscriptional level by binding to the 3'-UTR of target mRNA [9, 15-18]. miRNAs are critical regulators of abundant biological processes such as apoptosis, differentiation, and chemoresistance [19-22]. Several miRNAs are regulated in many diseases, including AD, Parkinson's disease, spinal cord injuries, brain trauma and tumors [23-27]. Recently, miRNAs were also reported to participate in the differentiation and proliferation of NSCs [12, 28, 29]. For example, Wu et al. [30]. illustrated that miR-374b modulated NSC differentiation and growth by regulating Hes1. Chen et al. [31]. noted that miR-132 acted as a moderator of neurite outgrowth, cell differentiation and self-renewal of NSCs. Recently, growing evidence has suggested that miR-153-3p induces immune dysregulation by suppressing PELI1 expression in MSCs (mesenchymal stem cells) that are separated from systemic lupus erythematosus patients [32]. However, the potential functional role of miR-153-3p in the fate of NSCs remains unclear.

In our study, we illustrated that miR-153-3p inhibited NSC differentiation and proliferation and proinflammatory cytokine release by targeting GPR55 expression in NSCs.

MATERIALS AND METHODS

Cell culture and transfection

NSCs were separated and cultured as described previously [33]. Cells were separated from five rat embryos and placed in medium supplemented with N2, bFGF and EGF. Our study was approved by The Affiliated Yan'An Hospital of Kunming Medical University. The miR-153-3p control, inhibitor and their control plasmids were obtained from GenePharma (China) and transfected into cells with Lipofectamine 3000 at a concentration of 10 nmol/l.

qRT-PCR

Total RNA, including small RNA and mRNAs, was separated from NSCs using a TRIzol kit (Thermo Fisher, Inc., USA). The miRNA and mRNA levels were determined by RT-qPCR. RT-qPCR analysis was performed using a SYBR Premix kit (Takara, China) and the 7900HT system. U6 was used as an internal control for miRNA, and GAPDH was used as a control for mRNA. The $2^{-\Delta\Delta CT}$ method was performed to determine the relative expression of target genes. The primer sequences were as follows: Tuj1, 5'-AGCAA GGTGC GTGAG GAGTA-3' (forward) and 5'- AAGCC GGGCA TGAAG AAGT-3' (reverse); Nestin 5'-GATCT AAACA GGAAG GAAAT CCAGG-3' and 5'-TCTAGT GTCTC ATGGC TCTGGT TTT-3': GFAP 5'-CAACG TTAAG CTAGC CCTGG ACAT-3', and 5'-CTCAC CATCC CGCAT CTCCA CAGT-3' and GAPDH 5'-ATTCC ATGGC ACCGT CAAGG CTGA-3', and 5'-TTCTC CATGG TGGTG AAGAC GCCA-3'.

Dual luciferase assay

The wild-type 3'-UTR and mutant 3'-UTR of GPR55 containing the predicted binding site of miR-153-3p were amplified by PCR and inserted into the pMIR-REPORT luciferase plasmid. Lipofectamine-2000 was utilized for transfection with miR-153-3p control or mimic and the wild-type and mutant 3'-UTRs of GPR55 as described previously. Luciferase activity was detected using a luciferase reporter kit (Promega, USA).

ELISA

After treatment, the cell culture supernatant was obtained to measure the levels of proinflammatory cytokines such as TNF- α , IL-1 β and IL-6 by using ELISA kits (Cambridge, UK).

Proliferation assay

Cells were plated in 96-well dishes and were allowed to continue growing for 0, 1, 2 and 3 days after treatment. Cell growth was detected using Cell Counting Kit-8 (Dojindo, China), and the cells were incubated with CCK-8 reagent (10%) for 3 hours at 37° C. The absorbance was measured using a microplate reader at 450 nm.

Immunofluorescence

Cells were fixed in paraformaldehyde (4%) for half an hour at room temperature and then washed in PBS (phosphate-buffered saline) 3 times. After 1 hour of blocking in Triton X-100 (0.2%) and goat serum (3%) in PBS, the cells were incubated with anti-nestin, anti-Tuj1 and anti-GFAP (1:400; Millipore, USA) at 4° C overnight. After washing 3 times in PBS, the cells were incubated with secondary antibodies. The cells were visualized with fluorescence microscope.

Statistical analysis

Experimental statistics were presented as means±standard deviation. Statistical significance (P<0.05) was analyzed by ANOVA or Student's t-test using the SPSS software system (Chicago, USA).

RESULTS

miR-153-3p is decreased and GPR55 is overexpressed during NSC differentiation

qRT-PCR data showed that miR-153-3p was decreased during NSC differentiation (Figure 1A). Moreover, GPR55 was upregulated during NSC differentiation (Figure 1B). IL-1 β (50 ng/ml) induced miR-153-3p expression in NSCs by two-fold (Figure 1C, p<0.01), and GPR55 was downregulated in NSCs after treatment with IL-1 β compared with that in the control group by two-fold (Figure 1D, p<0.01).

GPR55 is a direct gene target of miR-153-3p

qPCR illustrated that miR-153-3p was overexpressed in NSCs after treatment with the miR-153-3p mimic compared with that in the miR-NC group (Figure 2A, p<0.001). This result suggested that the efficiency of

miR-153-3p was high. By searching bioinformatic TargetScan 7.2 (<u>http://www.targetscan.org/vert 72/</u>), we identified one potential target site between miR-153-3p and the GPR55 3'-UTR (Figure 2B). We also showed that these sequences were conserved among different species (Figure 2B). Ectopic miR-153-3p expression suppressed GPR55 expression in NSCs (Figure 2C, p<0.01). Luciferase reporter analysis noted that elevated expression of miR-153-3p significantly inhibited the luciferase value of the WT reporter plasmid but did not change the luciferase value of the mut reporter plasmid (Figure 2D, p<0.01).

miR-153-3p suppresses NSC differentiation and proliferation

The expression of miR-153-3p was downregulated in NSCs after treatment with the anti-miR-153-3p mimic (Figure 3E, p<0.001). Ectopic expression of miR-153-3p

inhibited NSC proliferation (Figure 3A, p<0.001), and miR-153-3p suppression increased NSC growth (Figure 3F, p<0.01). Additionally, miR-153-3p overexpression decreased nestin expression (Figure 3B, p<0.01) and miR-153-3p knockdown induced nestin expression (Figure 3G, p<0.01) in NSCs. Furthermore, we illustrated that ectopic miR-153-3p expression suppressed Tuj1 (Figure 3C, p<0.01) and GFAP (Figure 3D, p<0.01) and that miR-153-3p suppression enhanced Tuj1 (Figure 3H, p<0.01) and GFAP (Figure 3I, p<0.01) in NSCs. Taken together, these data showed that miR-153-3p inhibited cell differentiation and proliferation in NSCs.

miR-153-3p induces proinflammatory cytokine release

The concentrations of TNF- α , IL-1 β and IL-6 were upregulated in NSCs after treatment with the miR-153-3p





mimic (Figure 4A, p<0.001). However, the knockdown of miR-153-3p suppressed the levels of TNF- α , IL-1 β and IL-6 in NSCs (Figure 4B, p<0.01). These data suggested that miR-153-3p induced proinflammatory cytokine release.

miR-153-3p inhibits NSC differentiation and proliferation by targeting GPR55 expression

Because GPR55 is an NSC regulator, we speculated that miR-153-3p might act on these functions by regulating GPR55 expression. To prove this hypothesis, several gain and loss function experiments were performed. The GPR55 agonist O-1602 promoted cell proliferation compared with the vehicle group (Figure 5A, p<0.01), and the GPR55 antagonist ML-193 inhibited cell growth compared with the vehicle group (Figure 5F, p<0.01) in miR-153-3p-treated NSCs. The GPR55 agonist O-1602 increased nestin (Figure 5B, p<0.05), Tuj1 (Figure 5C, p<0.05) and GFAP (Figure 5D, p<0.05) expression compared with the vehicle group, and the GPR55 antagonist ML-193 decreased nestin (Figure 5G, p<0.05), Tuj1 (Figure 5H, p<0.05) and GFAP (Figure 5I, p<0.05) expression compared with the vehicle group in miR-153-3p-treated NSCs. These data were also confirmed using immunocytochemical staining (Figure 5E). These results showed that miR-153-3p inhibited NSC differentiation and proliferation by targeting GPR55 expression.

DISCUSSION

Previous studies have illustrated that miRNAs regulate NSC differentiation, neuronal maturation and proliferation [10, 34, 35]. For example, Wu et al. [30]. illustrated that miR-374b modulates NSC differentiation and growth by regulating Hes1. Chen et al. [31]. noted that miR-132 acts as a moderator of neurite outgrowth, cell differentiation and self-renewal of NSCs. Xue et al. [36]. indicated that miR-145 protects NSC function by regulating the MAPK signaling pathway to remediate rat cerebral ischemic stroke. Channakkar et al. [37]. showed that miR-137 modulates NSC fate via the regulation of mitochondrial dynamics. However, the potential



Figure 2. GPR55 is a direct gene target of miR-153-3p. (A) The expression of GPR55 was determined by qRT-PCR. (B) One potential target site was found between miR-153-3p and GPR55. These sequences were conserved between different species. (C) The expression of GPR55 was determined by qRT-PCR. (D) Luciferase reporter analysis noted that elevated expression of miR-153-3p significantly inhibited the luciferase value of the WT reporter plasmid but did not change the luciferase value of the mut reporter plasmid. **p<0.01 and ***p<0.001. Error bars represent the s.d. of relative experiment from n=3 replicates.

functional role of miR-153-3p in the fate of NSCs remains unclear. miR-153-3p modulates cisplatin resistance and cell growth through Nrf-2 in esophageal carcinoma [38]. Li et al. [39]. illustrated that miR-153-3p modulates ovarian carcinoma progression by regulating MCL1 expression. Sun et al. [40]. indicated that miR-153-3p promotes glioma cell radiosensitivity by modulating BCL2. A previous study showed that IL-1 β induces miR-153 expression in beta cells and that IL-1 β plays critical roles in the fate of NSCs [41–43]. In the present study, we noted that miR-153-3p is decreased during NSC differentiation and that IL-1 β induces miR-153-3p expression in NSCs. Ectopic expression of miR-

153-3p inhibited NSC growth and differentiation into astrocytes and neurons. Elevated expression of miR-153-3p induced the release of proinflammatory cytokines, such as TNF- α , IL-1 β and IL-6, in NSCs. These results indicated that miR-153-3p plays critical roles in the cell differentiation and self-renewal of NSCs.

GPR55 is a lipid-sensing receptor that plays important roles in cell mobilization, invasion and cell cycle progression in tumor development. Wang et al. [44]. indicated that CID16020046 (GPR55 antagonist) protects against inflammation induced by ox-LDL in HAECs (aortic endothelial cells). Saliba et al. [45].



Figure 3. miR-153-3p suppresses NSC differentiation and proliferation. (A) Ectopic expression of miR-153-3p inhibited NSC proliferation. (B) Overexpression of miR-153-3p decreased nestin expression. (C) The expression of Tuj1 was detected by qRT-PCR. (D) The expression of GFAP was measured by qRT-PCR. (E) The expression of miR-153-3p was measured by qRT-PCR. (F) The suppression of miR-153-3p increased NSC growth. (G) Nestin expression was measured by qRT-PCR. (H) The expression of Tuj1 was detected by qRT-PCR. (I) The expression of GFAP was measured by qRT-PCR. *p<0.05, **p<0.01 and ***p<0.001. Error bars represent the s.d. of relative experiment from n=3 replicates.

illustrated that several compounds with antagonistic activities of GPR55 suppress PGE2 release in microglia. Recently, Hill et al. [46]. showed that GPR55 activation promotes NSC proliferation and differentiation into

neuronal cells. Moreover, they found that a GPR55 agonist defends against neurogenesis rate reductions in NSCs induced by IL-1 β . GPR55 activation suppresses inflammatory cytokine expression in NSCs [47]. In our



Figure 4. miR-153-3p induces proinflammatory cytokine release. (A) The concentration levels of TNF- α , IL-1 β and IL-6 were upregulated in NSCs after treatment with the miR-153-3p mimic. (B) Knockdown of miR-153-3p suppressed the concentration levels of TNF- α , IL-1 β and IL-6 in NSCs. **p<0.01 and ***p<0.001. Error bars represent the s.d. of relative experiment from n=3 replicates.



Figure 5. miR-153-3p inhibits NSC differentiation and proliferation by targeting GPR55 expression. (A) Cell proliferation was measured using CCK-8 analysis. (B) Nestin expression was determined by qRT-PCR. (C) The expression of Tuj1 was detected by qRT-PCR. (D) The expression of GFAP was measured by qRT-PCR. (E) The GPR55 antagonist ML-193 inhibited cell growth compared with the vehicle group in miR-153-3p-treated NSCs. (F) Nestin expression was determined by qRT-PCR analysis. (G) The expression of Tuj1 was detected by qRT-PCR. (H) The expression of GFAP was measured by qRT-PCR. *p<0.05 and **p<0.01. Error bars represent the s.d. of relative experiment from n=3 replicates.

study, we searched for bioinformatic targets and identified one potential target site between miR-153-3p and the GPR55 3'-UTR. Luciferase reporter analysis noted that the elevated expression of miR-153-3p significantly inhibited the luciferase value of the WT reporter plasmid but did not change the luciferase value of the mut reporter plasmid. Moreover, we showed that ectopic expression of miR-153-3p suppresses GPR55 expression in NSCs. Furthermore, miR-153-3p inhibited NSC differentiation and proliferation by targeting GPR55 expression. However, more experiments must be performed on human NSCs in the future. These results provide novel insights into the modulation of GPR55 and its cell function in the development of NSCs.

In summary, our results noted the involvement of miR-153-3p in modulating the differentiation and growth of NSCs. It also illustrated that miR-153-3p inhibits NSC differentiation and proliferation and proinflammatory cytokine release by targeting GPR55 expression in NSCs. These data suggest that miR-153-3p acts as a clinical target for neurodegenerative disease therapeutics.

AUTHOR CONTRIBUTIONS

Xiaolin Dong and Yanping Li performed experiments, Xiaolin Dong, Hui Wang, Liping Zhan, Qingyun Li, Yang Li, Gang Wu, Huan Wei, Yanping Li, design of the study, conceived and drafted the manuscript, analysed the data, Xiaolin Dong and Yanping Li wrote and revised the paper.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FUNDING

Our study was supported by the Special fund for the applied basic research of Yunnan Science and Technology Department associated with Kunming Medical University. NO. 2019FE001(-102).

ETHICAL STATEMENT

The study was approved by The Affiliated Yan'An Hospital of Kunming Medical University.

REFERENCES

 Zhang R, Zhang Q, Niu J, Lu K, Xie B, Cui D, Xu S. Screening of microRNAs associated with Alzheimer's disease using oxidative stress cell model and different strains of senescence accelerated mice. J Neurol Sci. 2014; 338:57–64. https://doi.org/10.1016/j.jns.2013.12.017 PMID:<u>24423585</u>

- Fang M, Wang J, Zhang X, Geng Y, Hu Z, Rudd JA, Ling S, Chen W, Han S. The miR-124 regulates the expression of BACE1/β-secretase correlated with cell death in Alzheimer's disease. Toxicol Lett. 2012; 209:94–105. <u>https://doi.org/10.1016/j.toxlet.2011.11.032</u> PMID:22178568
- Long JM, Ray B, Lahiri DK. MicroRNA-153 physiologically inhibits expression of amyloid-β precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. J Biol Chem. 2012; 287:31298–310. <u>https://doi.org/10.1074/jbc.M112.366336</u> PMID:<u>22733824</u>
- Meng F, Dai E, Yu X, Zhang Y, Chen X, Liu X, Wang S, Wang L, Jiang W. Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease. J R Soc Interface. 2013; 11:20131057. <u>https://doi.org/10.1098/rsif.2013.1057</u> PMID:24352679
- Cheng C, Li W, Zhang Z, Yoshimura S, Hao Q, Zhang C, Wang Z. MicroRNA-144 is regulated by activator protein-1 (AP-1) and decreases expression of Alzheimer disease-related a disintegrin and metalloprotease 10 (ADAM10). J Biol Chem. 2013; 288:13748–61. <u>https://doi.org/10.1074/jbc.M112.381392</u> PMID:23546882
- Fang M, Zhang P, Zhao Y, Liu X. Bioinformatics and coexpression network analysis of differentially expressed lncRNAs and mRNAs in hippocampus of APP/PS1 transgenic mice with Alzheimer disease. Am J Transl Res. 2017; 9:1381–91. PMID:28386363
- Malyshok N, Mankovska O, Kashuba V. Prediction of ANRIL long non-coding RNA sponge activity in neuroblastoma and Alzheimer disease. FEBS J. 2016; 283:282.
- Tan SL, Ohtsuka T, González A, Kageyama R. MicroRNA9 regulates neural stem cell differentiation by controlling Hes1 expression dynamics in the developing brain. Genes Cells. 2012; 17:952–61. <u>https://doi.org/10.1111/gtc.12009</u> PMID:23134481
- Cui Y, Xiao Z, Han J, Sun J, Ding W, Zhao Y, Chen B, Li X, Dai J. MiR-125b orchestrates cell proliferation, differentiation and migration in neural stem/progenitor cells by targeting Nestin. BMC

Neurosci. 2012; 13:116. https://doi.org/10.1186/1471-2202-13-116 PMID:<u>23016664</u>

- Wang Y, Jiaqi C, Zhaoying C, Huimin C. MicroRNA-506-3p regulates neural stem cell proliferation and differentiation through targeting TCF3. Gene. 2016; 593:193–200. <u>https://doi.org/10.1016/j.gene.2016.08.026</u> PMID:27538704
- Pham JT, Gallicano GI. Specification of neural cell fate and regulation of neural stem cell proliferation by microRNAs. Am J Stem Cells. 2012; 1:182–95. PMID:23671807
- 12. Li X, Feng R, Huang C, Wang H, Wang J, Zhang Z, Yan H, Wen T. MicroRNA-351 regulates TMEM 59 (DCF1) expression and mediates neural stem cell morphogenesis. RNA Biol. 2012; 9:292–301. <u>https://doi.org/10.4161/rna.19100</u> PMID:22336716
- Brett JO, Renault VM, Rafalski VA, Webb AE, Brunet A. The microRNA cluster miR-106b~25 regulates adult neural stem/progenitor cell proliferation and neuronal differentiation. Aging (Albany NY). 2011; 3:108–24. <u>https://doi.org/10.18632/aging.100285</u> PMID:<u>21386132</u>
- 14. Rybak A, Fuchs H, Smirnova L, Brandt C, Pohl EE, Nitsch R, Wulczyn FG. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stemcell commitment. Nat Cell Biol. 2008; 10:987–93. <u>https://doi.org/10.1038/ncb1759</u>
 PMID:<u>18604195</u>
- Liu J, Githinji J, Mclaughlin B, Wilczek K, Nolta J. Role of miRNAs in neuronal differentiation from human embryonic stem cell-derived neural stem cells. Stem Cell Rev Rep. 2012; 8:1129–37. <u>https://doi.org/10.1007/s12015-012-9411-6</u> PMID:<u>23054963</u>
- Wang G, Pan J, Zhang L, Wei Y, Wang C. Long noncoding RNA CRNDE sponges miR-384 to promote proliferation and metastasis of pancreatic cancer cells through upregulating IRS1. Cell Prolif. 2017; 50:e12389. https://doi.org/10.1111/cpr.12389 PMID:28940804
- 17. Yu L, Zhang J, Guo X, Li Z, Zhang P. MicroRNA-224 upregulation and AKT activation synergistically predict poor prognosis in patients with hepatocellular carcinoma. Cancer Epidemiol. 2014; 38:408–13. <u>https://doi.org/10.1016/j.canep.2014.05.001</u> PMID:<u>24923856</u>
- 18. Yang XW, Zhang LJ, Huang XH, Chen LZ, Su Q, Zeng WT, Li W, Wang Q. miR-145 suppresses cell invasion in

hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatol Res. 2014; 44:551–9. https://doi.org/10.1111/hepr.12152 PMID:23621665

- Xu L, Beckebaum S, Iacob S, Wu G, Kaiser GM, Radtke A, Liu C, Kabar I, Schmidt HH, Zhang X, Lu M, Cicinnati VR. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol. 2014; 60:590–8. <u>https://doi.org/10.1016/j.jhep.2013.10.028</u> PMID:<u>24211739</u>
- 20. Wang L, Yao J, Zhang X, Guo B, Le X, Cubberly M, Li Z, Nan K, Song T, Huang C. miRNA-302b suppresses human hepatocellular carcinoma by targeting AKT2. Mol Cancer Res. 2014; 12:190–202. <u>https://doi.org/10.1158/1541-7786.MCR-13-0411</u> PMID:<u>24337067</u>
- Wang SC, Lin XL, Li J, Zhang TT, Wang HY, Shi JW, Yang S, Zhao WT, Xie RY, Wei F, Qin YJ, Chen L, Yang J, et al. MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA. PLoS One. 2014; 9:e101330.

https://doi.org/10.1371/journal.pone.0101330 PMID:24992599

- Shen G, Rong X, Zhao J, Yang X, Li H, Jiang H, Zhou Q, Ji T, Huang S, Zhang J, Jia H. MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma. Carcinogenesis. 2014; 35:2748–55. <u>https://doi.org/10.1093/carcin/bgu208</u> PMID:<u>25280563</u>
- Geekiyanage H, Chan C. MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid β, novel targets in sporadic Alzheimer's disease. J Neurosci. 2011; 31:14820–30. <u>https://doi.org/10.1523/JNEUROSCI.3883-11.2011</u> PMID:<u>21994399</u>
- Kanagaraj N, Beiping H, Dheen ST, Tay SS. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins. Neuroscience. 2014; 272:167–79.

https://doi.org/10.1016/j.neuroscience.2014.04.039 PMID:24792712

 Yang Z, Xu J, Zhu R, Liu L. Down-Regulation of miRNA-128 Contributes to Neuropathic Pain Following Spinal Cord Injury via Activation of P38. Med Sci Monit. 2017; 23:405–11.

https://doi.org/10.12659/msm.898788 PMID:28114268

- 26. Chen L, Dong R, Lu Y, Zhou Y, Li K, Zhang Z, Peng M. MicroRNA-146a protects against cognitive decline induced by surgical trauma by suppressing hippocampal neuroinflammation in mice. Brain Behav Immun. 2019; 78:188–201. https://doi.org/10.1016/j.bbi.2019.01.020 PMID:<u>30685530</u>
- Fu X, Zhang L, Dan L, Wang K, Xu Y. LncRNA EWSAT1 promotes ovarian cancer progression through targeting miR-330-5p expression. Am J Transl Res. 2017; 9:4094–103. PMID:28979684
- Cui Y, Xiao Z, Chen T, Wei J, Chen L, Liu L, Chen B, Wang X, Li X, Dai J. The miR-7 identified from collagen biomaterial-based three-dimensional cultured cells regulates neural stem cell differentiation. Stem Cells Dev. 2014; 23:393–405. https://doi.org/10.1089/scd.2013.0342 PMID:24200387
- Gioia U, Di Carlo V, Caramanica P, Toselli C, Cinquino A, Marchioni M, Laneve P, Biagioni S, Bozzoni I, Cacci E, Caffarelli E. Mir-23a and mir-125b regulate neural stem/progenitor cell proliferation by targeting Musashi1. RNA Biol. 2014; 11:1105–12. <u>https://doi.org/10.4161/rna.35508</u> PMID:<u>25483045</u>
- Wu X, Zhao X, Miao X. MicroRNA-374b promotes the proliferation and differentiation of neural stem cells through targeting Hes1. Biochem Biophys Res Commun. 2018; 503:593–9. <u>https://doi.org/10.1016/j.bbrc.2018.06.044</u> PMID:<u>29902458</u>
- 31. Chen D, Hu S, Wu Z, Liu J, Li S. The Role of MiR-132 in Regulating Neural Stem Cell Proliferation, Differentiation and Neuronal Maturation. Cell Physiol Biochem. 2018; 47:2319–30. <u>https://doi.org/10.1159/000491543</u> PMID:<u>29982261</u>
- 32. Li D, Li X, Duan M, Dou Y, Feng Y, Nan N, Zhang W. MiR-153-3p induces immune dysregulation by inhibiting PELI1 expression in umbilical cord-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Autoimmunity. 2020; 53:201–9. <u>https://doi.org/10.1080/08916934.2020.1750011</u> PMID:32321315
- 33. Zheng J, Yi D, Shi X, Shi H. miR-1297 regulates neural stem cell differentiation and viability through controlling Hes1 expression. Cell Prolif. 2017; 50:e12347.
 <u>https://doi.org/10.1111/cpr.12347</u>
 PMID:<u>28464358</u>
- 34. Jiao S, Liu Y, Yao Y, Teng J. miR-124 promotes proliferation and differentiation of neuronal stem cells through inactivating Notch pathway. Cell Biosci.

2017; 7:68. https://doi.org/10.1186/s13578-017-0194-y PMID:<u>29238518</u>

- 35. Jiang D, Du J, Zhang X, Zhou W, Zong L, Dong C, Chen K, Chen Y, Chen X, Jiang H. miR-124 promotes the neuronal differentiation of mouse inner ear neural stem cells. Int J Mol Med. 2016; 38:1367–76. <u>https://doi.org/10.3892/ijmm.2016.2751</u> PMID:<u>28025992</u>
- Xue WS, Wang N, Wang NY, Ying YF, Xu GH. miR-145 protects the function of neuronal stem cells through targeting MAPK pathway in the treatment of cerebral ischemic stroke rat. Brain Res Bull. 2019; 144:28–38.

https://doi.org/10.1016/j.brainresbull.2018.08.023 PMID:<u>30179678</u>

- Channakkar AS, Singh T, Pattnaik B, Gupta K, Seth P, Adlakha YK. MiRNA-137-mediated modulation of mitochondrial dynamics regulates human neural stem cell fate. Stem Cells. 2020; 38:683–97. <u>https://doi.org/10.1002/stem.3155</u> PMID:<u>32012382</u>
- Zuo J, Zhao M, Fan Z, Liu B, Wang Y, Li Y, Lv P, Xing L, Zhang X, Shen H. MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma. Thorac Cancer. 2020; 11:738–47. <u>https://doi.org/10.1111/1759-7714.13326</u> PMID:32012470
- Li C, Zhang Y, Zhao W, Cui S, Song Y. miR-153-3p regulates progression of ovarian carcinoma *in vitro* and *in vivo* by targeting MCL1 gene. J Cell Biochem. 2019; 120:19147–58. <u>https://doi.org/10.1002/jcb.29244</u>
- PMID:<u>31297886</u>40. Sun D, Mu Y, Piao H. MicroRNA-153-3p enhances cell radiosensitivity by targeting BCL2 in human glioma.
- radiosensitivity by targeting BCL2 in human glioma. Biol Res. 2018; 51:56. <u>https://doi.org/10.1186/s40659-018-0203-6</u> PMID:<u>30537994</u>
- Sun Y, Zhou S, Shi Y, Zhou Y, Zhang Y, Liu K, Zhu Y, Han X. Inhibition of miR-153, an IL-1β-responsive miRNA, prevents beta cell failure and inflammation-associated diabetes. Metabolism. 2020; 111:154335. <u>https://doi.org/10.1016/j.metabol.2020.154335</u> PMID:<u>32795559</u>
- 42. Sharma KD, Schaal D, Kore RA, Hamzah RN, Pandanaboina SC, Hayar A, Griffin RJ, Srivatsan M, Reyna NS, Xie JY. Glioma-derived exosomes drive the differentiation of neural stem cells to astrocytes. PLoS One. 2020; 15:e0234614. https://doi.org/10.1371/journal.pone.0234614

PMID:<u>32649728</u>

- 43. Han MJ, Lee WJ, Choi J, Hong YJ, Uhm SJ, Choi Y, Do JT. Inhibition of neural stem cell aging through the transient induction of reprogramming factors. J Comp Neurol. 2021; 529:595–604. <u>https://doi.org/10.1002/cne.24967</u> PMID:32510600
- 44. Wang Y, Pan W, Wang Y, Yin Y. The GPR55 antagonist CID16020046 protects against ox-LDL-induced inflammation in human aortic endothelial cells (HAECs). Arch Biochem Biophys. 2020; 681:108254. <u>https://doi.org/10.1016/j.abb.2020.108254</u> PMID:<u>31904362</u>
- 45. Saliba SW, Jauch H, Gargouri B, Keil A, Hurrle T, Volz N, Mohr F, van der Stelt M, Bräse S, Fiebich BL. Antineuroinflammatory effects of GPR55 antagonists in LPS-activated primary microglial cells. J Neuroinflammation. 2018; 15:322. <u>https://doi.org/10.1186/s12974-018-1362-7</u> PMID:30453998

46. Hill JD, Zuluaga-Ramirez V, Gajghate S, Winfield M, Persidsky Y. Activation of GPR55 increases neural stem cell proliferation and promotes early adult hippocampal neurogenesis. Br J Pharmacol. 2018; 175:3407–21.

https://doi.org/10.1111/bph.14387 PMID:29888782

47. Hill JD, Zuluaga-Ramirez V, Gajghate S, Winfield M, Sriram U, Rom S, Persidsky Y. Activation of GPR55 induces neuroprotection of hippocampal neurogenesis and immune responses of neural stem cells following chronic, systemic inflammation. Brain Behav Immun. 2019; 76:165–81.

https://doi.org/10.1016/j.bbi.2018.11.017 PMID:<u>30465881</u>